Claims
- 1. A stable 1,2-dioxetane selected from the group consisting of: where R1 is selected from the group consisting of alkyl, aryl, aralkyl, alkaryl, heteroalkyl, heteroaryl, cycloalkyl, cyclohetelroalkyl, alkyletheralkyl, alkyletheraryl, alkyl(etheralkyl)2, alkyl(etheralkyl)3, alkyletherhaloalkyl, alkyl(etherhaloalkyi)2, alkylalkene, alkylalkyne, arylalkene, arylalkyne, halogenated alkyl(mono, di, tri or any position in normal or branched or cyclic chain), alkylalcohol, alkylnitrile, alkylamine, alkylacid (mono or dibasic) or the inorganic salts thereof, haloalkylalcohol, haloalkylnitrile, haloalkylamine, haloalkylacid (mono or dibasic) or inorganic salts, linker-flourescent molecule, linker-antibodies, linker-antigen, linker-biotin, linker-avidin, linker-protein or linker-carbohydrates or linker-lipids; Y is a hydrogen, alkyl, acetate, t-butyldimethylsilyl or an enzyme cleaveable group or an antibody cleaveable group: R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl, arylalkyl or substituted arylalkyl; X is chloro- or hydrogen and Z is hydrogen.
- 2. The 1,2dioxetane of claim 1, which is any of:[(4-methoxy)4-(3-phosphoryloxyphenyl)]spiro[1,2 dioxetane-3,13′-(8-n-propyl)tricyclo[7.3.1.02,7)tridec-2,7-ene], disodium salt; [(4-methoxy)4-(3-phosphoryloxyphenyl)]Spiro[1,2-dioxetane-3,13′-tricyclo[7.3.1,02,7]tridec-2,7-ene], disodium salt; [(4methoxy)-4-(3-phosphoryloxyphenyl]spiro[1,2-dioxetane-3,2′-adamantan-4,5ene], disodium salt; (4-(2,2,2-trifluoroethoxy)-4-(3-phosphoryloxyphenyl)]spiro[1,2-dioxetane-3,13′-tricyclo[7.3.1.02,7]tridec-2,7-ene], disodium salt; [4-(2-phenoxyethoxyl)-4-(3phosphoryloxyphenyl)spiro[1,2-dioxetane3 1 3′-tricyclo[7.3. 1. 02,7]tridec-2,7-ene], disodium salt; [(4-methoxy]-4-(3-phosphoryloxy-4-chlorophenyl)]spiro[1,2-dioxetane-3, 1 3′-tricyclo[7.3.1, 02,7]tridec-2,7-ene], disodium salt; and [(4-methoxy)-4-(3-phosphoryloxyphenyl)]Spiro [1,2-dioxetane-3,9′-(2,4-diphenylbicyclo[3.3.1]non-2-ene)], disodium salt.
- 3. A method for generating light which comprises:(a) providing a stable 1,2 dioxetane of the formulae: where R1 is selected from the group consisting of alkyl, aryl, aralkyl, alkaryl, heteroalkyl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkyletheralkyl, alkyletheraryl, alkyl(etheralkyl)2, alkyl(etheralkyl)3, alkyletherhaloalkyl, alkyl(etherhaloalkyl)2, alkylalkene, alkylalkyne, arylalkene, arylalkyne, halogenated alkyl(mono, di, tri or any position in normal or branched or cyclic chain), alkylalcohol, alkylnitrile, alkylamine, alkylacid (mono or dibasic) or the inorganic salts thereof, haloalkylalcohol, haloalkylnitrile, haloalkylamine, haloalkylacid (mono or dibasic) or inorganic salts, linker-flourescent molecule, linker-antibodies, linker-antigen, linker-biotin, linker-avidin, linker-protein or linker-carbohydrates or linker-lipids; Y is a hydrogen, alkyl, acetate, t-butyldimethylsilyl or an enzyme cleaveable group or an antibody cleaveable group; R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl, arylalkyl or substituted arylalkyl; X is chloro-or hydrogen and Z is hydrogen, and (b) decomposing the stable 1,2-dioxetane with an activating agent to give the corresponding carbonyl group.
- 4. The method of claim 1 wherein the 1,2dioxtane is any one of the following:[(4methoxy)-4-(3phosphoryloxyphenyl)]spiro [1,2-dioxetane-3,13′-(8-n-propyl)tricyclo[7.3.1.02,7)tridec-2,7-ene], disodium salt; [(4-methoxy)-4-(3-phosphoryloxyphenyl)]Spiro [1,2-dioxetane-3,13′-tricyclo[7.3.1,02,7]tridec-2,7ene], disodium salt; [(4methoxy)-4-(3-phosphoryloxyphenyl]spiro[1,2-dioxetane-3,2′-adamantan-4,5-ene], disodium salt; [4(2,2,2-trifluoroethoxy)-4-phosphoryloxyphenyl)]spiro[1,2-dioxetane-3, 1 3′-tricyclo[7.3.1,02,7]tridec-2,7-ene], disodium salt; [4-(2phenoxyethoxyl)-4-(3-phosphoryloxypheny)spiro[1,2-dioxetane3 1 3′-tricyclo[7.3.1.02,7]tridec-2,7-ene], disodium salt; [(4-methoxy)-4-(3-phosphoryloxy-4-chlorophenyl)]spiro[1,2-dioxetane-3, 1 3′-tricyclo[7.3.1,02,7]tridec-2,7-ene], disodium salt; and [(4-methoxy)-4-(3-phosphoryloxyphenyl)]Spiro[1,2-dioxetane-3,9′-(2,4diphenylbicyclo[3.3.1]non-2-ene)], disodium salt.
CROSS REFERENCE TO RELATED APPLICATION
This application is a national application based on PCT Application, Serial No. 99/20590, filed Sep. 8, 1999, which is a completion application of U.S. provisional patent application Serial No. 6-0/099,693, filed Sep. 8, 1998 for “Chemiluminescent 1,2 dioxetanes”, the disclosures of which are hereby incorporated by reference.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
5004565 |
Schaap |
Apr 1991 |
A |
5112960 |
Bronstein et al. |
May 1992 |
A |
5225584 |
Brooks et al. |
Jul 1993 |
A |
5578253 |
Schaap et al. |
Nov 1996 |
A |
5679803 |
Bronstein et al. |
Oct 1997 |
A |
5721370 |
Akhavan-Tafti et al. |
Feb 1998 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/099693 |
Sep 1998 |
US |